Evidence map›Paper›PMID 26221300›Full record

ArticleInternational journal of clinical and experimental medicine2015

(18)F-FDG avid volumes on pre-radiotherapy FDG PET as boost target delineation in non-small cell lung cancer.

Ang Gao, Shijiang Wang, Zheng Fu, Xindong Sun, Jinming Yu, Xue Meng

Abstract read
In one paragraph

Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Scientific reports · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ang GaoDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences Jinan, China.
Shijiang WangDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences Jinan, China.
Zheng FuDepartment of Nuclear Medicine, Shandong Cancer Hospital and Institute Jinan, China.
Xindong SunDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences Jinan, China.
Jinming YuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences Jinan, China.
Xue MengDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo investigate whether during/post-radiotherapy FDG uptake locations within tumors is likely identified using a pre-radiotherapy scan for non-small cell lung cancer (NSCLC), ultimately enabling confirm that a suitable metabolically active sub-volume pre-radiotherapy of the primary tumor for radiation boosting target.

methodsPatients with a pathologically proven inoperable stage II-III NSCLC were enrolled. For each patient, one pre-radiotherapy (pre-RT) plus one following 40Gy during-radiotherapy (during-RT) or post-radiotherapy (post-RT) FDG PET/CT scans were available. On pre-RT scan, the high FDG uptake region were auto-delineated using several percentage of the maximal standardized uptake value (SUVmax) thresholds, varying from 40% to 70%. On during-RT scan, FDG uptake region is delineated by 40% SUVmax, manual method respectively. With the FDG-positive areas on post-RT images is defined as 80% SUVmax. The overlap fractions (OFs) were calculated between pre-RT scan and during-RT or post-RT scan. Semi-quantitative assessment was used to determine SUVmax and metabolic tumor volume (MTV). The SUVmax changes during-RT representing the radiotherapy (RT) early metabolic response is attainable. Then, a spearman correlation was used to analysis the correlation between percentage changes in SUVmax during-RT and SUVmax-threshold definition volume pre-RT.

resultsOf those 7 patients, a total of 16 FDG-PET scans were acquired. 5 patients were received pre-RT and during-RT scan, while 2 of these 5 patients underwent both post-RT scan. 2 patients were received FDG-PET/CT scan pre-RT and post-RT. The pre-RT scan threshold delineations of 50% SUVmax had a large OF with the 40% SUVmax threshold and manual method delineation on the during-RT scan, 74.3% and 84.4%, respectively. Comparably, the 80% SUVmax on the post-RT scan also largely corresponded (OF > 72%) with the 50% SUVmax threshold and the volume was small compared to the gross tumor volume (GTV), accounting for 29.4%. However, the 50% SUVmax threshold was not correlate with the percentage change in SUVmax (P > 0.05).

conclusionsA pre-RT FDG-PET scan allows for the identification of during- and post-RT FDG uptake locations. The volume defined by 50% SUVmax may be a suitable threshold for dose escalation.

Indexed as

boost target delineationdose paintingFDG-PETNon-small cell lung cancerSUV-threshold

Identifiers

PMID26221300
PMCPMC4509245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.